Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2021-04-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司2020年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2020年度独立董事述职报告" which translates to "2020 Annual Independent Directors' Work Report." It details the independent directors' duties, attendance, opinions on company matters such as related party transactions, external guarantees, fundraising usage, nomination and remuneration of directors and senior management, performance forecasts, appointment of accounting firms, profit distribution plans, internal control execution, and overall evaluation and suggestions. The content is a detailed report on the independent directors' activities and opinions for the year 2020, which is a form of management or board report rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive report on governance and management oversight. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4624 characters) supports it being a full report rather than a brief announcement.
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司2020年度非经营性资金占用及其他关联资金往来的专项说明
Regulatory Filings
2021-04-23 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司部分募集资金投资项目实施方式变更的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding changes in the implementation method of certain fundraising investment projects by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It references regulatory guidelines related to fundraising management and usage, provides detailed financial data, project investment changes, contract terms, and audit opinions. The document is not a full annual or interim report but a specialized report focused on fundraising project changes and compliance. It is not a simple announcement or certification but a substantive advisory report. This fits the category of Capital/Financing Update (CAP), as it deals with changes in the use of raised funds and related investment projects.
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司独立董事关于部分募投项目实施方式变更的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from independent directors regarding changes in the implementation method of certain fundraising investment projects. It references compliance with regulatory guidelines on the use of raised funds and confirms the legality and appropriateness of the changes. The content focuses on governance and regulatory compliance related to fundraising projects, not on financial results, audit, or management changes. It is not a full report but an opinion statement related to capital use. This fits best under Capital/Financing Update (CAP) as it concerns changes in fundraising project implementation and use of raised funds.
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司关于部分募投项目实施方式变更的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding changes in the implementation method of certain projects funded by previously raised capital. It details the original fundraising, the use of funds, the changes in project execution, and the reasons for these changes. It includes financial figures related to the fundraising and project budgets, but it is not a full financial report or audit. The document also mentions approvals by the board and supervisory committee and states that the matter will be submitted to the shareholders' meeting for approval. The content focuses on changes to capital investment projects and fundraising usage, which aligns with updates on company fundraising or capital structure changes. The document is not an annual report, interim report, earnings release, or audit report. It is not a simple announcement of a report publication but a substantive update on capital use. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5966 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司2021年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes for the first quarter of 2021. The report is unaudited as stated in the text. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content and structure match the characteristics of an Interim / Quarterly Report, which provides comprehensive financial data for a period shorter than a full fiscal year. Therefore, the document is classified as an Interim / Quarterly Report (IR).
2021-04-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.